Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • Risvodetinib (IkT-148009) for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Sep 20, 2023 8:30am EDT

Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity

Aug 24, 2023 8:30am EDT

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 22, 2023 8:05am EDT

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 21, 2023 8:30am EDT

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 17, 2023 8:30am EDT

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 14, 2023 4:20pm EDT

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 07, 2023 8:05am EDT

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Jul 17, 2023 4:05pm EDT

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 29, 2023 9:29am EDT

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 22, 2023 8:05am EDT

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap